A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

May 24, 2016

Thunderbolt Pharma, Inc., a Vitesse Biologics Company, Acquires Rights to BAFF/APRIL Dual Antagonist Program from Astellas Pharma Inc.

-First company established under Vitesse Biologics, an innovative collaboration formed by Baxalta, Mayo Clinic and Velocity Pharmaceutical Development

BANNOCKBURN, Ill., SAN FRANCISCO, Calif., and TOKYO, Japan, May 24, 2016 – Baxalta Incorporated (NYSE: BXLT), Velocity Pharmaceutical Development, LLC (VPD) and Astellas Pharma Inc. (TSE:4503)...

Read more
May 23, 2016

Astellas, Daiichi Sankyo, and Takeda Announce Research Collaboration on Establishing Biomarker Database on Healthy Adults

Tokyo and Osaka, Japan, May 23, 2016 ---Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka; Headquarters: Tokyo; TSE: 4503; "Astellas"), Daiichi Sankyo Company, Limited (President and...

Read more
May 23, 2016

THE RESULTS FROM A ONE YEAR TREATMENT OF REPATHA PRESENTED AT THE ANNUAL MEETING OF THE JAPAN DIABETES SOCIETY (JDS 2016)

Read more
May 11, 2016

Astellas Announces Cancellation of Treasury Shares

Read more
May 11, 2016

Notice Regarding the Continuation of a Performance-linked Stock Compensation Scheme

Read more

Show per page

Discover more

Media contacts

Return to media homepage

Subscribe to news alerts

Choose Language

News